CRISPR/Cas9-Mediated Gene Therapy in Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".
Deadline for manuscript submissions: 30 May 2024 | Viewed by 592
Special Issue Editors
Interests: mesenchymal stem cells; bone and soft tissue tumors; BMP signaling; wnt signaling; cancer drug resistance; noncoding RNAs; bone and skeletal biology; cancer metastasis; regenerative medicine; gene therapy
Special Issues, Collections and Topics in MDPI journals
Interests: cancer precision medicine; DNA damage & repair; CRISPR/Cas-gene editing; iPSC & organoid; neurodevelopment
Interests: identification of novel biomarkers and drug targets using CRISPR KO screens has the potential to significantly impact cancer treatment; leading to more effective prognosis and therapies for human canc
Special Issue Information
Dear Colleagues,
The advent of cutting-edge CRISPR/Cas-based gene editing techniques and related therapeutic applications comes with an unprecedented opportunity to treat monogenic diseases, even complex diseases like cancers. The CRISPR/Cas-based gene therapy for different types of cancers requires the careful engineering of genome-editing toolsets, delivery strategies, spatiotemporal control of Cas protein expression, off-target mitigation, and efforts to address cytotoxicity and immunogenicity. These therapeutic approaches greatly vary between liquid tumors and solid-state tumors. More mechanistic and translational research will be beneficial for knowledge base advancement regarding this breakthrough gene therapy technique. Thus, in this Special Issue, we invite you to submit your original research articles and review articles discussing about diverse components of CRISPR/Cas-based gene therapy. These include, but are not limited to:
- The choice of CRISPR/Cas system for safer cancer gene therapy;
- Spatio-temporal control of gene regulation in cancers through CRISPR/Cas;
- Controlling Cas protein expression in in vivo gene therapy application;
- Viral and non-viral delivery system;
- Application of CAR-T cell therapy in liquid and solid-state tumors;
- Engineering natural killer (NK) cells for cancer immunotherapy;
- Strategies to mitigate cytotoxicity and immunotoxicity in CRISPR/Cas gene therapy.
Dr. Tong-Chuan He
Dr. Subhajit Giri
Dr. Sharad Awasthi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CRISPR/Cas
- liquid tumor
- solid-state cancer
- gene therapy
- AAV
- CAR-T
- lipid nanoparticle
- immunotherapy
- cytotoxicity
